Goldman Sachs Group Inc reaffirmed their sell rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Tuesday. The firm currently has a GBX 3,800 ($50.49) price objective on the biopharmaceutical company’s stock.

AZN has been the topic of a number of other reports. Morgan Stanley reaffirmed an overweight rating and issued a GBX 5,600 ($74.41) target price on shares of AstraZeneca plc in a research note on Friday, June 23rd. UBS AG set a GBX 5,150 ($68.43) target price on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Tuesday, June 27th. Shore Capital reaffirmed a hold rating on shares of AstraZeneca plc in a research note on Wednesday, June 21st. Credit Suisse Group reaffirmed a neutral rating and issued a GBX 5,000 ($66.44) target price on shares of AstraZeneca plc in a research note on Monday, June 19th. Finally, Liberum Capital reaffirmed a buy rating and issued a GBX 5,500 ($73.08) target price on shares of AstraZeneca plc in a research note on Thursday, July 13th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. AstraZeneca plc presently has an average rating of Hold and a consensus price target of GBX 5,172.64 ($68.73).

AstraZeneca plc (LON:AZN) opened at 5162.00 on Tuesday. The firm’s market capitalization is GBX 65.35 billion. The company’s 50-day moving average is GBX 4,923.51 and its 200-day moving average is GBX 4,914.37. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00.

TRADEMARK VIOLATION WARNING: “AstraZeneca plc (AZN) Receives Sell Rating from Goldman Sachs Group Inc” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://theolympiareport.com/2017/10/21/astrazeneca-plc-azn-receives-sell-rating-from-goldman-sachs-group-inc.html.

In related news, insider Nazneen Rahman purchased 39 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The shares were acquired at an average price of GBX 4,370 ($58.07) per share, for a total transaction of £1,704.30 ($2,264.55).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.